Skip to main content
Premium Trial:

Request an Annual Quote

Applied Microarrays Licenses OGT's Southern Array IP; Can Now Make, Sell CodeLink Chips

NEW YORK (GenomeWeb News) — Oxford Gene Technology has licensed its Southern array patents to Applied Microarrays, OGT said today.
 
The IP comprises the fundamental patents enabling companies to manufacture and market oligonucleotide microarrays, and will allow Applied Microarrays to fabricate, market, and distribute the CodeLink line it acquired in May from GE Healthcare.
 
AMI, a 1-year-old firm headed by a former Motorola Life Sciences researcher, also gets OEM rights to manufacture custom arrays for third parties under their own brand name. 
 
The license will remain valid for the patents’ lifetime.
 
Financial details were not disclosed.
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.